TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.

TherapeuticsMD Price Performance

TXMD stock opened at $1.59 on Monday. TherapeuticsMD has a 1-year low of $1.43 and a 1-year high of $3.07. The business’s 50 day simple moving average is $1.69 and its 200 day simple moving average is $1.82.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.23 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP grew its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. 30.74% of the stock is currently owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.